Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families. VGL101, our lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. We are also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.
View Top Employees from Vigil NeuroscienceWebsite | http://www.vigilneuro.com |
Employees | 77 (54 on RocketReach) |
Founded | 2020 |
Address | 100 Forge Rd Suite 700, Watertown, Massachusetts 02472, US |
Industry | Biotechnology Research |
Looking for a particular Vigil Neuroscience employee's phone or email?
Jennifer Ziolkowski is the CFO of Vigil Neuroscience.
54 people are employed at Vigil Neuroscience.
Vigil Neuroscience is based in Watertown, Massachusetts.